Immunotherapy and Targeted Therapy: What Is the Difference?

Immunotherapy and targeted therapy are both systemic cancer treatments, meaning they may reach cancer cells in different parts of the body. They differ mainly in what they act upon.

Immunotherapy helps the immune system recognize, control, or destroy cancer. Cancer cells may avoid immune attack by hiding their abnormal features or activating signals that tell immune cells to stand down. Immunotherapy attempts to remove that disguise, release those biological brakes, or provide immune cells with better equipment.

Targeted medications act on specific genes, proteins, receptors, enzymes, or signaling pathways that help cancer cells grow and survive. Instead of attacking every rapidly dividing cell, a targeted drug looks for a particular molecular weakness. It is less like dropping a net over an entire neighborhood and more like disabling the faulty control panel in one building.

The categories sometimes overlap. Certain monoclonal antibodies attach to a target on cancer cells while also recruiting the immune system. Medicine, like a kitchen junk drawer, does not always keep everything in perfectly labeled compartments.

How Immunotherapy Works

Immune Checkpoint Inhibitors

Immune checkpoints are natural control systems that prevent the immune system from attacking healthy tissue too aggressively. Some cancers exploit checkpoints such as PD-1, PD-L1, CTLA-4, and LAG-3 to avoid destruction.

Checkpoint inhibitors block one of these signals, allowing immune cellsparticularly T cellsto remain active against the cancer. Examples include pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab, and relatlimab-containing treatment. The right drug depends on the diagnosis and treatment setting; they are not interchangeable items on a pharmacy buffet.

These medications may be used alone or combined with chemotherapy, targeted drugs, radiation, or another checkpoint inhibitor. They have produced durable responses in some patients, although many cancers do not respond and reliable prediction remains an active area of research.

CAR T-Cell Therapy

Chimeric antigen receptor T-cell therapy, usually shortened to CAR T-cell therapy, begins with collecting a patient’s T cells. A laboratory modifies those cells so they carry receptors designed to recognize a particular target on cancer cells. The cells are multiplied and returned to the patient.

CAR T-cell therapy is used mainly for certain leukemias, lymphomas, and multiple myeloma. It can produce powerful responses, but it also requires specialized monitoring because complications may include cytokine release syndrome, infections, low blood counts, and neurologic effects.

Tumor-Infiltrating Lymphocyte Therapy

Tumor-infiltrating lymphocyte therapy, or TIL therapy, uses immune cells collected from a patient’s tumor. The cells that appear capable of recognizing the cancer are expanded in large numbers and infused back into the patient after preparatory treatment. The first FDA-approved TIL therapy was authorized for certain adults with previously treated, unresectable or metastatic melanoma.

Other Forms of Immunotherapy

The immunotherapy family also includes certain monoclonal antibodies, immune-modulating drugs, cytokines, cancer treatment vaccines, and oncolytic virus therapy. Each operates differently. A treatment vaccine, for example, is intended to stimulate an immune response against an existing cancer; it is not the same as a vaccine used to prevent infection.

How Targeted Medications Work

Small-Molecule Inhibitors

Small-molecule drugs are compact enough to enter cells and interfere with internal enzymes or signaling pathways. Many are available as tablets or capsules. Their names often end in “-ib,” although decoding a medication entirely by its suffix is best left to oncologists, pharmacists, and unusually enthusiastic crossword players.

Examples include kinase inhibitors that block signals from EGFR, ALK, BRAF, MEK, RET, HER2, or BCR-ABL. Other targeted medications interfere with proteins involved in DNA repair, blood vessel formation, or cell-cycle control.

Monoclonal Antibodies

Monoclonal antibodies are laboratory-made proteins that usually attach to targets on the surface of cancer cells or in the surrounding environment. They may block growth signals, mark cancer cells for immune destruction, prevent tumors from forming blood vessels, or deliver another treatment directly to the cell.

Antibody-drug conjugates take the delivery concept further by connecting an antibody to a cancer-killing payload. The antibody recognizes a target, travels toward cells carrying it, and helps release the payload where it is needed. This does not eliminate effects on healthy tissue, but it can make drug delivery more selective.

Common Examples of Targeted Treatment

Targeted medications have become important in many cancers. Representative pairings include:

• Trastuzumab and other HER2-directed drugs for selected HER2-positive cancers.
• Osimertinib for certain non-small cell lung cancers with eligible EGFR mutations.
• Imatinib for cancers driven by targets such as BCR-ABL or particular KIT alterations.
• BRAF and MEK inhibitor combinations for selected cancers carrying BRAF V600 mutations.
• PARP inhibitors for some cancers with specific homologous recombination repair defects, including certain BRCA-related tumors.
• NTRK inhibitors for tumors with eligible NTRK gene fusions, regardless of where the cancer began.

This list is illustrative rather than a treatment menu. A drug that works beautifully for one molecular subtype may be uselessor unnecessarily riskywhen its target is absent. The National Cancer Institute maintains extensive cancer-specific listings because the number of approved targeted agents continues to expand.

Why Biomarker Testing Matters

Biomarker testing examines tumor tissue, blood, or another body fluid for genes, proteins, and molecular characteristics that may influence treatment. It may also be called molecular testing, genomic profiling, tumor profiling, or precision oncology testing.

For targeted therapy, testing may look for changes such as EGFR mutations, ALK fusions, HER2 amplification, BRAF mutations, or NTRK fusions. For immunotherapy, commonly considered markers include PD-L1 expression, microsatellite instability-high status, mismatch repair deficiency, andin selected situationstumor mutational burden.

A biomarker is not a guaranteed forecast. A positive result may increase the chance that a therapy will help without promising success. A negative result does not always exclude every immunotherapy option because treatment decisions may also depend on the cancer type, stage, regulatory indication, and combination being considered.

Tissue Biopsy Versus Liquid Biopsy

A tissue biopsy provides actual tumor cells and often supplies the most complete information. A liquid biopsy searches blood for tumor cells or fragments of tumor DNA. Liquid biopsy can be useful when tumor tissue is difficult to obtain, when a faster result is needed, or when doctors are looking for emerging resistance. However, a negative liquid biopsy may not mean that no actionable alteration exists; the tumor may simply be releasing too little material into the bloodstream.

Why Retesting May Be Recommended

Cancer can evolve during treatment. A recurrent or metastatic tumor may not have exactly the same molecular profile as the original cancer. Retesting can sometimes reveal a new target or a resistance mechanism that changes the treatment plan.

Who May Be Eligible?

Eligibility for immunotherapy or targeted medications is based on more than the name of the cancer. Oncologists typically consider:

• The exact cancer type, subtype, and stage.
• Biomarker and pathology results.
• Whether treatment is intended before surgery, after surgery, or for advanced disease.
• Previous treatments and how the cancer responded.
• Heart, lung, liver, kidney, immune, and bone marrow function.
• Current medications, supplements, and possible drug interactions.
• Autoimmune disease, organ transplantation, infection history, or pregnancy considerations.
• Whether an appropriate clinical trial is available.

Some people receive these medicines as their first systemic treatment. Others receive them after chemotherapy, surgery, radiation, hormone therapy, or another targeted drug. Combination therapy is common because different approaches may attack complementary weaknesses. It can also increase toxicity, so “more treatment” is not automatically “better treatment.”

Potential Benefits and Important Limitations

The major attraction of precision treatment is selectivity. When a cancer strongly depends on a particular target, blocking it may shrink tumors quickly or keep disease controlled for a meaningful period. Immunotherapy may generate long-lasting immune memory in some responders, allowing control to continue after treatment has stopped.

Nevertheless, neither approach works for everyone. A tumor may lack a treatable biomarker, contain several competing cell populations, or use alternative growth pathways. Even after an excellent initial response, resistant cells may survive and eventually multiply. Researchers are studying drug combinations, next-generation inhibitors, repeat molecular testing, and treatment sequencing to overcome resistance.

Another limitation is access. Complex testing, specialty infusions, cell therapy centers, frequent monitoring, and medication costs can create practical burdens. Financial navigators, social workers, pharmacists, patient-assistance programs, and insurance specialists can become as valuable as a fully charged phone during a long airport delay.

Side Effects of Immunotherapy

Immunotherapy side effects often result from immune activity against healthy organs. These immune-related adverse events may occur during treatment, weeks or months later, and occasionally after therapy has ended.

Possible effects include:

• Skin rash, itching, or blistering.
• Diarrhea, abdominal pain, or inflammation of the colon.
• Cough, shortness of breath, or lung inflammation.
• Abnormal liver tests or hepatitis.
• Thyroid, pituitary, adrenal, or pancreatic inflammation.
• Kidney, heart, eye, joint, muscle, or nervous system problems.
• Fatigue, fever, chills, and infusion reactions.

Many reactions are manageable when identified early. Treatment may involve pausing immunotherapy, using corticosteroids, replacing hormones, or adding other immune-suppressing medicine. Patients should never assume that severe diarrhea, breathing difficulty, chest pain, confusion, jaundice, sudden weakness, or an intense headache is “just part of treatment.” The oncology team needs to hear about new symptoms promptly.

Side Effects of Targeted Medications

“Targeted” does not mean “side-effect free.” Healthy cells may use some of the same proteins or pathways being blocked. Effects vary widely by drug class and may include:

• Diarrhea, nausea, appetite changes, or mouth sores.
• Acne-like rash, dry skin, sensitivity to sunlight, or nail changes.
• High blood pressure or bleeding problems.
• Hand-foot syndrome, causing redness or tenderness on the palms and soles.
• Liver, kidney, lung, or heart abnormalities.
• Slow wound healing.
• Low blood counts, fatigue, swelling, or muscle aches.

Monitoring may include blood pressure checks, blood tests, electrocardiograms, heart imaging, urine tests, eye examinations, or scans. Oral targeted medications must be taken exactly as prescribed. A pill can be powerful cancer therapy even when it arrives in an ordinary-looking bottle rather than an IV bag.

Questions to Ask Before Treatment

• What biomarker or clinical feature makes this treatment appropriate for me?
• Is the goal to cure the cancer, reduce recurrence risk, shrink it, or keep it controlled?
• Will I receive this medication alone or with other treatment?
• How and where is it given, and how long might treatment continue?
• Which symptoms require an immediate call?
• Could my prescriptions, antacids, vitamins, herbs, or foods interact with the drug?
• How will you determine whether it is working?
• What happens if the cancer becomes resistant?
• Should my tumor be tested again later?
• Are clinical trials or financial-support programs relevant?

Bring an updated medication list to appointments and consider taking notes or inviting a trusted person. Cancer consultations can produce an avalanche of unfamiliar terms, and even excellent memories occasionally decide to take the afternoon off.

Experiences With Immunotherapy and Targeted Medications

One of the most common experiences at the beginning of treatment is information overload. Patients may hear a sequence of letters and numbersPD-L1, HER2, EGFR, MSI, BRAFand wonder whether the oncology clinic has accidentally switched to airport codes. Understanding usually improves when the care team connects each marker to a simple question: Was this found in my cancer, and does it change my options?

Infusion days can be surprisingly uneventful. A patient may expect flashing equipment and dramatic medical activity, only to spend several hours in a comfortable chair while medication flows quietly through an IV. Bringing water, a snack, headphones, a charger, and an extra layer of clothing can make the day easier. Patients receiving cell therapy may have a far more intensive experience involving cell collection, preparatory chemotherapy, hospitalization, and close observation.

Oral targeted therapy creates a different routine. The medication is taken at home, but treatment still influences daily life. Some pills must be taken with food, others without it, and many have strict instructions about missed doses. Patients often find that a weekly pill organizer is not enough; alarms, a written log, or a medication app may prevent uncertainty about whether Tuesday’s dose actually happened or merely appeared in a very convincing dream.

Side effects can be unpredictable. One person may have only mild fatigue or a manageable rash, while another needs treatment paused for inflammation of the lungs, colon, liver, or endocrine glands. A useful habit is keeping a brief symptom diary that records when a problem began, whether it is worsening, and how it affects eating, sleep, movement, or bathroom habits. This provides more useful information than telling the nurse, “Something felt weird sometime last week.”

Patients also learn that reporting symptoms early is not complaining. Cancer teams would generally rather receive an unnecessary phone call than discover a serious immune reaction after it has progressed. The same principle applies to targeted drugs. New shortness of breath, severe diarrhea, yellowing of the skin, chest pain, confusion, fainting, unusual bleeding, or rapidly worsening weakness deserves prompt medical guidance.

Scan days can carry their own emotional weight. Some patients experience “scanxiety” before imaging and results appointments. A treatment may produce a rapid response, gradual stability, or no measurable benefit. With immunotherapy, imaging findings can occasionally be complicated by inflammation, so the oncologist considers symptoms, scan patterns, laboratory results, and timing rather than interpreting one number in isolation.

Another common experience is the need to adjust expectations. Precision medicine sounds as though every tumor arrives with a perfect molecular keyhole and every pharmacy owns the matching key. In reality, testing may find no actionable alteration, a promising drug may not work, or resistance may develop. None of these outcomes means that the patient did something wrong. Cancer biology is complicated, and treatment decisions are revised as new information appears.

Success can also create unexpected feelings. A person whose cancer remains controlled for years may still live with medication schedules, follow-up scans, financial concerns, lingering side effects, and fear of progression. Support groups, counseling, rehabilitation, nutrition services, palliative care, and survivorship programs can improve quality of life at any stage. Palliative care is not limited to end-of-life treatment; it can be used alongside active cancer therapy to control symptoms and support patients and families.

The most constructive experience is often partnership. Patients do not need to become molecular oncologists overnight, but they benefit from knowing the treatment name, its purpose, the major warning signs, and who to call after office hours. Caregivers can help by tracking appointments, recording questions, and noticing changes the patient may overlook. Good cancer care is a team sport, although thankfully nobody is required to wear matching jerseys.

Conclusion

Immunotherapy and targeted medications have changed cancer treatment by focusing on two powerful ideas: the immune system can sometimes be redirected against cancer, and a tumor’s molecular features can reveal vulnerabilities worth targeting. These treatments may offer longer control, fewer effects on certain healthy cells, or options when older therapies have stopped working.

They also require realistic expectations. Biomarker testing does not guarantee a match, targeted drugs can cause serious toxicity, immunotherapy can trigger inflammation in almost any organ, and cancers may develop resistance. The best treatment plan combines accurate testing, careful monitoring, rapid symptom reporting, and ongoing conversations with an experienced oncology team.